Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Gilles FreyerJ P Gérard

Abstract

Oxaliplatin could increase the efficacy of fluorouracil (5-FU)/folinic acid chemoradiotherapy in rectal cancer. We tested three dose levels to identify a feasible oxaliplatin dose for combination therapy. Between February 1998 and April 2000, we included 17 rectal adenocarcinoma patients in a single-center phase I study. Patients had T4 rectal carcinoma, T1-T3 disease with colostomy refusal, or potentially operable T2/T3 M1 requiring local treatment. Pelvic radiotherapy was 45 Gy over 5 weeks, 1.8 Gy/fraction, with concomitant chemotherapy weeks 1 and 5. Chemotherapy was oxaliplatin 80, 100, or 130 mg/m2 2-hour infusion on day 1 followed by L-folinic acid 100 mg/m2/d intravenous bolus, and 5-FU 350 mg/m2/d continuous infusion on days 1 to 5 (FolfoR1). Six patients refusing surgery received additional contact radiotherapy +/- brachytherapy. Dose escalation proceeded if less than two of six patients had dose-limiting toxicity (DLT) at a given dose-level. All except two patients completed treatment; patients at level 1 (prolonged grade 1 thrombocytopenia) and level 3 (prolonged cold-related dysesthesia) had no second chemotherapy course. Median follow-up is 14 months (range, 2 to 28 months). One elderly patient at dose level 1 had...Continue Reading

References

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·J S PentaD L Trump
Mar 14, 1991·The New England Journal of Medicine·J E KrookJ A Mailliard
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·J M ExtraM Marty
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T L SmithM N Raber
Feb 1, 1996·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J P GerardJ C Thalabard
Apr 16, 1998·Seminars in Radiation Oncology·J P GerardF Mornex
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y FrancoisJ P Gerard
Feb 8, 2000·International Journal of Radiation Oncology, Biology, Physics·J F BossetJ C Horiot
Jun 6, 2000·International Journal of Radiation Oncology, Biology, Physics·N A JanjanJ Skibber
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti

❮ Previous
Next ❯

Citations

Feb 4, 2006·Diseases of the Colon and Rectum·Cecile OrtholanJean P Gerard
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian ChauJacqueline Oates
Feb 19, 2015·Current Oncology Reports·Nathan Nussbaum, Ivy Altomare
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlo Aschele, Sara Lonardi
Apr 17, 2007·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·M H Wallace, R Glynne-Jones
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin R Weiser
May 4, 2012·Journal of Cellular Biochemistry·Julio Cesar Madureira de-Freitas-JuniorJosé Andrés Morgado-Díaz
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claus RödelRolf Sauer
Jun 17, 2006·Cancer Investigation·Aaron C Spalding, Theodore S Lawrence
Oct 7, 2006·American Journal of Clinical Oncology·Kenyon MeadowsWilliam M Mendenhall
Apr 26, 2005·Current Oncology Reports·Tyvin A RichJerome Landry
Aug 14, 2008·Expert Review of Anticancer Therapy·Jaume CapdevilaJosep Tabernero
Aug 20, 2003·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·B D Minsky
Aug 20, 2003·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·David Sebag-Montefiore
Dec 15, 2010·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·A D ThukralV Bar Ad
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kjersti Flatmark, Anne Hansen Ree
Mar 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ricky A SharmaWilliam P Steward
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlo AscheleLuca Boni
Nov 4, 2004·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·O ReerinkG A P Hospers
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre GérardGilles Freyer
Nov 28, 2002·Clinical Colorectal Cancer·Kevin P McMullen, A William Blackstock

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.